摘要 |
Numerous studies have documented that medications which increase brain serotonin (5-HT) are effective anorectic agents which help obese patients lose weight and which also decrease craving for sweets and carbohydrates. Evidence from other studies also indicate that increases in brain 5-HT may help decrease craving for alcohol and cocaine. 5-hydroxy-L-tryptophan, abbreviated 5-HTP, is the immediate precursor of serotonin (5-HT). When administered in combination with an inhibitor of peripheral decarboxylase such as carbidopa, 5-HTP increases brain serotonin. Increases in synaptic 5-HT decreases the firing rate of 5-HT neurons via stimulation of inhibitory 5-HT1a receptors located on the cell bodies in the raphe. This serves as a negative feedback loop. The clinically available beta adreneric receptor antagonist medication pindolol is also a 5-HT1a antagonist, and can be used to increase the ability of 5-HTP to increase brain 5-HT. Previous studies with 5-HTP used doses exceeding 50 mg per day. When 5-HTP was used in combination with carbidopa, the dose of carbidopa was in excess of 50 mg per day. One novel aspect of the invention are the doses of the 5-HTP and carbidopa: much lower daily doses than have been used before are effective in decreasing appetite, decreasing craving for food and for promoting weight loss. The second novel aspect of the invention relates to the concurrent use of pindolol along with the 5-HTP/Carbidopa, which enhances the effectiveness of the 5-HTP/Carbidopa combination.
|